**Clover Biopharmaceuticals, Ltd.**
**三葉草生物製藥有限公司**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 2197)**

# VOLUNTARY ANNOUNCEMENT
# CLOVER DOSES FIRST PATIENT WITH SCB-219M IN PHASE 1 TRIAL FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Clover Biopharmaceuticals, Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company doses first patient with SCB-219M in Phase 1 trial for chemotherapy-induced thrombocytopenia ("**CIT**").

The Company is pleased to announce that on June 14, 2022, the first patient has been dosed with SCB-219M, an innovative thrombopoietin receptor agonist ("**TPO-RA**") mimetic Fc-fusion protein, in a Phase 1 clinical trial to evaluate the safety, tolerability, immunogenicity, pharmacokinetics ("**PK**") and efficacy of SCB-219M in cancer patients with CIT. The Company received the IND (Investigational New Drug) approval for SCB-219M as a Class I new drug from CDE (Center for Drug Evaluation (國家藥品監督管理局藥品審評中心)) in December 2021.

The Phase 1 trial is a multi-center, open-label, dose escalation and dose expansion study, that will explore the safety, tolerability, immunogenicity, PK and efficacy of SCB-219M administered subcutaneously in cancer patients with CIT. Interim safety and recommendations for Phase 2 dosing is anticipated in the first half of 2023.

**About SCB-219M**

SCB-219M is an innovative human TPO-RA produced from CHO cells based on the Company's Fc-fusion technology protein platform. In pre-clinical studies, SCB-219M has demonstrated an extended serum half-life and favorable pharmacokinetics/pharmacodynamics ("**PK/PD**") profile that supports weekly dosing possibility of the drug. In comparison, current standard of cares for CIT largely require either daily injection or drug administration.

**About CIT**

CIT is a platelet count disorder typically observed in cancer patients undergoing chemotherapy. CIT negatively affects overall chemotherapy treatment outcomes due to therapeutic interruption and serious, potentially fatal bleeding events. Primary treatment options for CIT in the United States and Europe include platelet transfusion, providing short-term stability of platelet levels, and in China include recombinant human interleukin 11 ("**rh IL-11**") and recombinant humanized thrombopoietin ("**rh-TPO**"), which requires daily injection for no more than 14 days due to potential significant adverse reactions such as anti-drug antibody generation ("**ADAs**").

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
**Clover Biopharmaceuticals, Ltd.**
**Dr. Peng LIANG**
*Chairman of the Board*

Shanghai, PRC, June 14, 2022

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG and Mr. Dong LYU as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*